SGLT2 Inhibitors Explained for Cardio-Renal Benefits

Discover the key cardio-renal benefits that SGLT2 inhibitors can deliver in managing heart and kidney health effectively.

Abstract

In this educational post, I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, present the latest evidence-based findings on sodium-glucose cotransporter-2 (SGLT2) inhibitors and their profound cardiometabolic and renal benefits. We will explore the intricate connections between type 2 diabetes, heart failure, and chronic kidney disease (CKD)—what I call the “ties that bind”—and understand the profound physiological impact they have on the body. Drawing from contemporary clinical trials and translational physiology research, I explain why SGLT2 inhibitors are reshaping standards of care. I will break down their mechanism of action, explaining how they not only lower blood sugar but also offer significant protective benefits for the heart and kidneys. We will review the evidence-based applications, patient selection criteria, and important clinical considerations for these drugs. Finally, I will highlight how integrative chiropractic care, functional medicine, and personalized rehabilitation fit into a comprehensive protocol designed to optimize outcomes, reduce symptom burden, and improve quality of life. This multidisciplinary approach is made possible through close collaboration with our Medical Director, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine) (NPI #1164426749, Texas MD License #J2933), who has over 40 years of internist experience and provides medical oversight at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas. Together, we combine medical management, chiropractic care, functional nutrition, and personal injury rehabilitation to deliver advanced, patient-centered care.

My Journey into Diabetes and Integrative Care

I stepped into the world of diabetes long before I held my clinical titles. As a child, I cared for my grandmother, a stroke survivor, and witnessed firsthand how consistent medication use, thoughtful food choices, and daily blood sugar checks could change a life. One night, when she complained of leg pain, I applied a menthol rub to soothe her discomfort and found what I thought were granules of sand on her skin. When I turned on the light, those granules moved—they were ants. That moment struck me deeply: impaired sensation, poor circulation, and neuropathy could invite wounds and infection without warning. It was a visceral lesson about the realities of diabetes complications and the importance of integrative, proactive care.

That formative experience shaped my clinical passion: make every intervention logical to the patient and the provider, teach the physiology clearly, and ensure our treatments move the needle on outcomes—A1c, kidney function, heart failure symptoms, and daily function.

Our Integrated Clinical Team: Medical Oversight and Collaborative Practice

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, our multidisciplinary model blends medical and integrative care. I am Dr. Alex Jimenez, and my journey in healthcare has been driven by a passion for understanding the root causes of chronic disease and providing holistic, patient-centered solutions. With a diverse background as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), Family Nurse Practitioner (FNP-BC), and certifications in Functional Medicine (CFMP, IFMCP), Applied Traumatic Neurology (ATN), and Clinical Case Studies in Traumatology (CCST), I am dedicated to bridging the gaps between different medical disciplines.

A cornerstone of this collaborative model is our partnership with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of invaluable experience to our clinic. She serves as our Medical Director and Collaborative Physician, providing essential medical oversight that enables us to integrate advanced medical treatments, such as management of SGLT2 inhibitors, alongside our core services. This integrated model allows us to blend the best of different disciplines. While I may focus on the biomechanical, neurological, and functional aspects of health through integrative chiropractic care and functional medicine, Dr. Cardenas provides the allopathic medical expertise necessary for comprehensive diagnosis and treatment, particularly for complex internal medicine cases.

Our model combines Dr. Cardenas’s expertise in internal medicine with my background in chiropractic, functional medicine, and rehabilitation. This allows us to address not just the symptoms but the entire physiological ecosystem of our patients. Our team communicates across disciplines, aligns treatment goals, and monitors outcomes such as A1c, eGFR, albuminuria, BNP/NT-proBNP, blood pressure, and functional capacity. Whether you are dealing with a personal injury, a chronic condition like diabetes, or complex cardiorenal issues, our team works together to create a unified and powerful treatment plan.

The Overwhelming Burden of Chronic Disease: More Than Just Numbers

To truly appreciate the significance of new therapies, we must first grasp the scale of the problem we are facing. Let’s step back and look at the global impact of chronic kidney disease (CKD) and heart failure, two conditions often intertwined with type 2 diabetes.

Based on data spanning 1990 to 2017, the statistics are staggering, and we can only assume these numbers have risen further as of June 16, 2026.

• Chronic Kidney Disease (CKD):

• • Global Prevalence: Over 697.5 million people worldwide.
  • Financial Impact: In the United States alone, the annual cost was an estimated $48 billion.

• Heart Failure:

• • Global Prevalence: Affecting 64 million people.
  • Financial Impact: A staggering global cost of $346 billion per year.

These numbers are alarming, but the human cost is even more profound. Researchers use a metric called the Disability-Adjusted Life Year (DALY) to quantify this. One DALY represents the loss of one year of full, healthy life due to premature death or disability.

• For CKD, the global burden was 35.8 million DALYs, meaning 35.8 million years of healthy life were lost.
• For heart failure, the numbers were even higher:

• • Ischemic Heart Disease: 182 million DALYs.
  • Hypertensive Heart Disease:5 million DALYs.
  • Cardiomyopathy & Myocarditis:14 million DALYs.

This is not just data on a page; it represents millions of lives cut short and families forever changed. It highlights the urgent need for treatments that can alter the course of these devastating diseases.

The Ties That Bind: Diabetes, Heart Failure, and Kidney Disease

When we reintroduce type 2 diabetes into this picture, the connections become undeniable. I call these conditions the “ties that bind” because of their deep, overlapping relationship. Whether one causes the other or they are simply correlated, their intersection is where we find our greatest opportunity to optimize treatment.

During my training as a Nurse Practitioner, I logged countless patient cases. A pattern quickly emerged. Whenever I entered the diagnosis code for type 2 diabetes, it was almost always followed by codes for hypertension, hyperlipidemia, CKD, or heart failure. This was the real-world manifestation of the inflammatory cascade and cardiovascular complications I had studied in textbooks.

• In the United States, an estimated 4 million adults have type 2 diabetes.
• Of these individuals, 20% to 40% also have CKD. That’s between 7 and 15 million people with declining kidney function.
• For these patients, progression to heart failure or other cardiovascular events is not a matter of if, but when. This has led to the coining of the term cardiorenal complications of diabetes.

Our integrated approach at Injury Medical Clinic is designed to address this triad. While Dr. Cardenas and I manage the metabolic and medical aspects, our chiropractic and rehabilitation services focus on improving neurological function, reducing systemic inflammation through manual therapies, and promoting physical activity—all of which help mitigate the progression of these interconnected diseases.

A Simple Analogy for a Complex Problem: The Pathophysiology of Cardiorenal Damage

Understanding the underlying physiology is key to appreciating why certain treatments work. When I explain this to my patients, I use a simple analogy to make a complex process relatable. I start by saying, “Diabetes causes high blood sugar.” Everyone knows that. Then I ask them to think about something very sweet, like honey or syrup.

“How would you describe that liquid?” I ask. The usual answer is “gooey,” “sticky,” or “thick.”

“Exactly,” I say. “It doesn’t flow easily; it oozes. Now, imagine that same thick, oozing liquid is your blood. How hard would your heart have to work to pump that sticky fluid through your body?”

They immediately understand. The heart must pump extra hard, increasing its workload to perform its basic function. This is the first stressor.

Next, I ask them to imagine holding a piece of hard candy in their mouth, pressed against the inside of their cheek, for an hour. “How would that spot feel afterward?”

They describe it as raw, irritated, or even hardened. “Sugar is inflammatory; it hardens everything in its path,” I explain. “Now, where does your blood go?”

“Everywhere,” they reply.

“So, everywhere your sugary blood travels, it causes inflammation and hardening. It hardens your blood vessels and scrapes the delicate filters in your kidneys.”

With this simple analogy, we can begin to understand the complex diagram of cardiorenal pathophysiology.

1. High Blood Sugar (Hyperglycemia): This increases blood volume as the body pulls water from cells (osmotic diuresis), making the heart work harder.
2. Increased Cardiac Workload & Blood Pressure: The heart struggles to pump the viscous blood, and the increased volume raises blood pressure.
3. Paradoxical Low Perfusion: Despite high pressure, the sticky blood results in poor tissue perfusion, especially in sensitive organs such as the kidneys.
4. RAAS Activation: Poor kidney perfusion triggers the Renin-Angiotensin-Aldosterone System (RAAS). Chronic activation of this system, particularly by angiotensin, causes harmful structural changes (remodeling) in the heart.
5. Kidney Damage: The kidneys suffer from both poor perfusion and the direct “scraping” effect of high sugar. A unique issue in diabetes is that the kidneys’ threshold for spilling sugar into the urine is “numbed.” Instead of getting rid of excess sugar, the diabetic kidney paradoxically reabsorbs it, worsening the hyperglycemia.
6. A Vicious Cycle: Damaged kidneys can’t filter waste or regulate fluid properly, leading to more water retention and higher blood pressure, which further stresses the heart. The heart is now being attacked from two sides: the direct effects of high blood sugar and the consequences of kidney failure.

The Game Changer: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Now that we understand the problem, we are ready to discuss the solution: SGLT2 inhibitors—such as empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin. These medications are the stars of our discussion today, representing a major leap forward in managing cardiorenal disease.

How Do SGLT2 Inhibitors Work?

SGLT2 is a transporter in the proximal renal tubules responsible for reabsorbing about 90 percent of filtered glucose. In diabetes, this reabsorption is upregulated, contributing to hyperglycemia. SGLT2 inhibitors work by blocking this protein. By inhibiting SGLT2, these medications prevent the kidneys from reabsorbing glucose. Instead, the excess sugar is flushed from the body in the urine.

Yet their benefits extend far beyond glucose. The key mechanisms include:

• Natriuresis and Osmotic Diuresis: Blocking SGLT2 increases sodium and glucose excretion. This produces mild diuresis, reduces plasma volume, and lowers interstitial fluid. Clinically, this reduces preload and improves symptoms in heart failure, thereby decreasing the risk of hospitalization (especially in HFrEF and HFpEF).
• Tubuloglomerular Feedback and Intrarenal Hemodynamics: Increased sodium delivery to the macula densa resets tubuloglomerular feedback. Afferent arteriolar tone increases, reducing intraglomerular pressure—protecting the glomerulus from hyperfiltration injury. This mechanism slows eGFR decline and reduces albuminuria, even in non-diabetic CKD. I explain this to patients using the analogy of a mesh filter. High pressure stretches the mesh, making the holes larger and allowing large molecules, such as proteins, to leak into the urine (microalbuminuria). By reducing this pressure, SGLT2 inhibitors help protect the kidneys and reduce protein spillage.
• Metabolic Flexibility and Substrate Shifts: Mild ketosis and improved fatty acid oxidation may occur. The heart may benefit from ketone bodies as efficient fuel under stress, potentially enhancing myocardial energetics in heart failure.
• Hematocrit and Erythropoietin Effects: SGLT2 inhibitors often increase hematocrit and hemoglobin, potentially through reduced plasma volume and stimulation of renal erythropoietin production, thereby improving oxygen delivery.
• Anti-inflammatory and Anti-fibrotic Signaling: Evidence suggests reduced inflammatory markers, decreased NLRP3 inflammasome activity, and attenuation of renal and cardiac fibrosis.

Approved Indications and Clinical Benefits

The benefits of SGLT2 inhibitors extend far beyond glucose control. The FDA has approved them for a range of indications:

• Improving glycemic control in type 2 diabetes.
• Reducing the risk of major adverse cardiovascular events (MACE).
• Decreasing hospitalization for heart failure.
• Slowing the decline of eGFR (kidney function) and reducing hospitalizations related to CKD.
• Improving cardiovascular outcomes in patients with heart failure, even those without diabetes. (Dapagliflozin is now approved for heart failure across the full spectrum of ejection fraction).

Evidence from Landmark Clinical Trials

Modern, well-designed trials demonstrate robust benefits across populations, often independent of glycemic status.

Cardiovascular Benefits

Three key trials highlight the powerful cardiovascular protection offered by SGLT2 inhibitors:

Clinical Trial	Medication	Key Finding (MACE Reduction)	Key Finding (Heart Failure Hospitalization Reduction)
EMPA-REG OUTCOME (Zinman et al., 2015)	Empagliflozin (Jardiance)	14% relative risk reduction	35% relative risk reduction
VERTIS CV (Cannon et al., 2020)	Ertugliflozin (Steglatro)	Non-inferior (no significant reduction)	30% relative risk reduction
CANVAS Program (Neal et al., 2017)	Canagliflozin (Invokana)	14% relative risk reduction	33% relative risk reduction
DAPA-HF (McMurray et al., 2019)	Dapagliflozin (Farxiga)	(Primary outcome was worsening HF/CV death)	30% reduction in worsening HF events
EMPEROR-Preserved (Anker et al., 2021)	Empagliflozin (Jardiance)	(Primary outcome was HF hosp/CV death)	21% reduction in primary outcome

These trials show that SGLT2 inhibitors significantly reduce the risk of heart attacks, strokes, and cardiovascular death, while dramatically lowering the chances of being hospitalized for heart failure.

Renal (Kidney) Benefits

The protective effects on the kidneys are just as impressive.

Clinical Trial	Medication	eGFR Inclusion Criteria	Primary Outcome Reduction (ESRD, Creatinine Doubling, Renal/CV Death)
CREDENCE (Perkovic et al., 2019)	Canagliflozin (Invokana)	30 to <90 mL/min/1.73m²	30% relative risk reduction
DAPA-CKD (Heerspink et al., 2020)	Dapagliflozin (Farxiga)	25 to 75 mL/min/1.73m²	39% relative risk reduction
EMPA-KIDNEY (The EMPA-KIDNEY Collaborative Group, 2022)	Empagliflozin (Jardiance)	> 20 to <45 mL/min/1.73m²	28% relative risk reduction

These studies prove that SGLT2 inhibitors are not just for diabetes—they are frontline agents for preserving kidney function in patients with CKD, with or without diabetes.

---

Cardiometabolic Risk *Causes & Effects*- Video

---

Clinical Guidelines: A Unified Voice

Leading health organizations have incorporated this powerful evidence into their treatment guidelines, creating a clear and unified recommendation.

• American Diabetes Association (ADA): For adults with type 2 diabetes and high cardiovascular risk or established heart/kidney disease, guidelines recommend an SGLT2 inhibitor or a GLP-1 receptor agonist. This recommendation stands irrespective of their A1c level, emphasizing the primary role of these drugs in organ protection.
• American Association of Clinical Endocrinology (AACE): The AACE guidelines echo this, stating that for patients with established or high risk for cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor or GLP-1 RA with proven efficacy should be prescribed independent of glycemic control.

The message is clear: we have moved beyond simply lowering blood sugar. The goal is now comprehensive cardiorenal risk reduction.

Integrative Chiropractic Care: How It Fits Clinically

Chiropractic care plays a critical role in our integrative model, particularly for patients with diabetes, heart failure, CKD, and personal injuries. The connection lies in the autonomic nervous system, musculoskeletal biomechanics, inflammation, and movement behavior:

• Autonomic Modulation: Gentle spinal adjustments influence sympathetic-parasympathetic balance. Improving vagal tone can lower resting heart rate, aid sleep quality, and reduce stress-related glycemic excursions.
• Biomechanics and Lymphatic Flow: Thoracic spine mobility affects ribcage mechanics and venous/lymphatic return. Improved mechanics reduce the burden of peripheral edema and improve exercise capacity, especially in heart failure.
• Pain Reduction and Activity Enablement: Correcting joint dysfunction reduces pain, allowing patients to increase physical activity safely. Increased daily movement enhances insulin sensitivity, lowers glucose variability, and improves mood.
• Neuroinflammation and Proprioception: Segmental dysfunction contributes to neurogenic inflammation and altered proprioception. Restoring segmental integrity can reduce nociceptive signaling, lower systemic stress hormones, and improve gait, which in turn can reduce the risk of falls and ulcers in patients with neuropathy.

From a systems perspective, chiropractic adjustments and neuromuscular rehabilitation help patients tolerate and benefit from SGLT2 therapy by improving mobility, function, and adherence to exercise prescriptions.

Functional Medicine and Rehabilitation Integration

We combine SGLT2 therapy with functional medicine protocols and phased rehabilitation to address upstream drivers and support safe recovery:

• Functional Nutrition: We implement low-glycemic, fiber-rich dietary patterns, tailor sodium and fluid intake to heart and kidney status, and teach skills like label reading and meal timing.
• Microbiome and Inflammation: We use targeted prebiotics, probiotics, and polyphenols to calm inflammatory signaling.
• Sleep and Stress Physiology: We deploy stress management, breathwork, and sleep hygiene protocols to improve metabolic resilience.
• Micronutrients: We optimize magnesium, vitamin D, omega-3s, and iron status to support cardiometabolic health.
• Phased Rehabilitation: For patients with injuries, our rehab programs progress from pain/edema control to motor control, strength, and, finally, functional return-to-work, with careful monitoring of cardiovascular and metabolic status.

A Patient’s Journey: The Modern Paradigm in Practice

To truly understand the evolution of diabetes care, let’s walk through a real-world case study of a patient we’ll call R.B.

The Initial Clinical Picture

When R.B. first came to our clinic, he was a 73-year-old Hispanic male with a 12-year history of type 2 diabetes, also struggling with hypertension, hyperlipidemia, and Stage 3b Chronic Kidney Disease (CKD). His health markers were alarming: an A1c of 10.2%, an eGFR of 43 mL/min/1.73 m^2, and daily blood sugar levels averaging 200-300 mg/dL. Paradoxically, he was also experiencing frightening episodes of nocturnal hypoglycemia. His fear of these lows caused him to “preemptively eat” throughout the day, creating a vicious cycle of daytime highs and nighttime lows. He was also adamant in his refusal to use a Continuous Glucose Monitor (CGM).

Crafting the Initial Treatment Plan: Education and Empowerment

Our first step was not to add another medication, but to focus on Diabetes Self-Management Education (DSME).

1. Addressing the Fear of Hypoglycemia: We broke the vicious cycle by discontinuing his glipizide (a sulfonylurea) and decreasing his Lantus (glargine) insulin dose.
2. Overcoming the CGM Barrier: I addressed his misconceptions about the CGM by showing him a demo unit. This simple act of showing, not just telling, completely eased his fear, and he left with a prescription for one.
3. Assessing Insulin Production: We ordered a C-peptide level, which confirmed his pancreas was still functioning—a crucial piece of information.

Progress and Adding a Key Player

Two weeks later, his blood sugar levels were averaging in the 180s, and the nocturnal lows had stopped. With his glucose levels more stable, it was now safe to add dapagliflozin (Farxiga) 5 mg daily, an SGLT2 inhibitor.

Three Months In: A Remarkable Turnaround

Three months after his initial visit, the lab results were nothing short of remarkable:

Metric	Initial Visit	3-Month Follow-Up
A1c	10.2%	8.2%
Creatinine	1.54 mg/dL	1.3 mg/dL
eGFR	43 mL/min	53 mL/min

His kidney function was visibly improving! At this stage, under Dr. Cardenas’s guidance, we switched him from a DPP-4 inhibitor to semaglutide (Ozempic) 0.5 mg weekly, a powerful GLP-1 receptor agonist.

Seven Months Later: Sustaining Success

At his seven-month follow-up, his transformation was continuing. His A1c was now 7.2%, his creatinine was within the normal range, and his eGFR was holding steady at 55 mL/min. Most impressively, he was achieving this control without needing his mealtime (lispro) insulin. The combination of the SGLT2 inhibitor and the GLP-1 receptor agonist was working so well that his own body could now manage his meals.

Important Considerations and Patient Education

While SGLT2 inhibitors are transformative, they require careful patient selection and thorough education. As a prescribing provider, I always discuss the following:

• Contraindications: History of Diabetic Ketoacidosis (DKA) and severe kidney disease (though eGFR cutoffs are expanding).
• Special Considerations:

• Sick Days & Surgery: We advise patients to temporarily hold the medication during acute illnesses or before surgery to reduce the risk of DKA.
• Genital Yeast and Urinary Tract Infections (UTIs): Because these drugs flush sugar into the urine, they can create a breeding ground for bacteria and yeast. Hydration is critical.
• Foot Infections: Based on clinical observation, I often pause the medication until a serious foot infection resolves and manage glucose through other means.
• Ketogenic Diet: Combining a keto diet with an SGLT2 inhibitor is a dangerous mix that can easily push a patient into DKA.

Clinical Collaboration: How Dr. Cardenas Guides Our Protocols

As Medical Director, Dr. Cardenas ensures:

• Appropriate patient selection for SGLT2 therapy.
• Coordination with cardiology and nephrology when needed.
• Diuretic adjustments and ACEi/ARB/ARNI alignment.
• Monitoring for infections, ketoacidosis risk, and renal function changes.
• Documentation and communication across providers.

This level of oversight is standard in high-performing integrative clinics, where an MD and chiropractor collaborate to deliver safe, effective, and patient-centered care.

Key Takeaways

• SGLT2 inhibitors deliver robust cardiorenal protection beyond glucose control.
• Physiological mechanisms—natriuresis, tubuloglomerular feedback, metabolic shifts—explain the real-world improvements.
• Integrative care with chiropractic, functional medicine, and rehabilitation maximizes benefits through autonomic balance, movement optimization, and root-cause nutrition.
• Medical oversight by an experienced internist, like Dr. Maria Guadalupe Cardenas, MD, is essential for safety and coordination.
• Education is the force multiplier that turns data into durable results.

The advent of SGLT2 inhibitors marks a paradigm shift in modern medicine. By understanding their mechanism, reviewing the robust evidence, and integrating them into a comprehensive, multidisciplinary care model, we can offer our patients a new level of protection against the devastating consequences of diabetes, heart failure, and kidney disease.

References

1. Anker, S. D., Butler, J., Filippatos, G., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
2. Cannon, C. P., Pratley, R., Dagogo-Jack, S., et al. (2020). Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine, 383(15), 1425–1435.
3. McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
4. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436–1446.
5. The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117–127.
6. Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128.
7. Neal, B., Perkovic, V., Mahaffey, K. W., et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644–657.
8. Perkovic, V., Jardine, M. J., Neal, B., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295–2306.
9. Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844.
10. Solomon, S. D., Claggett, B., Lewis, E. F., et al. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387(12), 1089–1098.
11. Wiviott, S. D., Raz, I., Bonaca, M. P., et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380(4), 347–357.

Learn more about my clinical observations and integrative approach:

• HealthCoach Clinic: healthcoach.clinic/
• Professional profile: www.linkedin.com/in/dralexjimenez/

SEO Tags: SGLT2 inhibitors, integrative chiropractic care, cardiorenal benefits, heart failure, chronic kidney disease, diabetes, empagliflozin, dapagliflozin, canagliflozin, functional medicine, rehabilitation, autonomic nervous system, tubuloglomerular feedback, osmotic diuresis, Mission Plaza Injury Medical Clinic, Injury Medical Clinic PA, El Paso Texas, internal medicine oversight, Dr. Alex Jimenez, Dr. Maria Cardenas, cardiorenal syndrome, Jardiance, Invokana, Farxiga, DALY, RAAS system, MACE, eGFR, ADA guidelines, AACE guidelines, multidisciplinary care, patient education, DKA risk, GLP-1 agonists, Ozempic, A1c, hypoglycemia, hyperglycemia, holistic health